Adipokines and lipoproteins: Modulation by antihyperglycemic and hypolipidemic agents

Metabolic Syndrome and Related Disorders

Volumn 12, Issue 1, 2014, Pages 1-10

  Rizvi, Ali A ^a   Nikolic, Dragana ^b   Sallam, Hanaa S ^c,d   Montalto, Giuseppe ^b   Rizzo, Manfredi ^a,b,e   Abate, Nicola ^d  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PALERMO   (Italy)

^c Suez Canal University   (Egypt)

^d University of Texas Medical Branch School of Medicine   (United States)

^e Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIOBESITY AGENT; LEPTIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ANTIDIABETIC ACTIVITY; BODY MASS; DRUG EFFECT; ENERGY METABOLISM; GLUCOSE HOMEOSTASIS; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MODULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; WAIST CIRCUMFERENCE;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; AZETIDINES; FIBRIC ACIDS; GLUCOSE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INCRETINS; INSULIN; INSULIN RESISTANCE; LIPIDS; LIPOPROTEINS; METABOLIC SYNDROME X; METFORMIN; NIACIN; THIAZOLIDINEDIONES;

EID: 84892545867     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2013.0090     Document Type: Review

References (187)

1. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 1999; 20:649-688 (Pubitemid 30650602)
2. Chandalia M, Abate N. Metabolic complications of obesity: Inflated or inflamed? J Diabetes Complications 2007;21:128-136
3. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129-139
4. Katsiki N, Mikhailidis DP, Gotzamani-Psarrakou A, et al. Effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide Y in patients with type 2 diabetes mellitus. Expert Opin Ther Targets 2011;15:401-420
5. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr2006;83:461S-465S. (Pubitemid 44713219)
6. Mikhailidis DP, Elisaf M, Rizzo M, et al. ''European panel on low density lipoprotein (LDL) subclasses'': A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: Executive summary. Curr Vasc Pharmacol 2011;9:531-532
7. Chu SH, Lee MK, Ahn KY, et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS One2012;7:e34710
8. Mikhailidis DP, Elisaf M, Rizzo M, et al. ''European panel on low density lipoprotein (LDL) subclasses'': A statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr Vasc Pharmacol 2011;9:533-571
9. van de Woestijne AP, Monajemi H, Kalkhoven E, et al. Adipose tissue dysfunction and hypertriglyceridemia: Mechanisms and management. Obes Rev 2011;12:829-840
10. Franssen R, Monajemi H, Stroes ES, et al. Obesity and dyslipidemia. Endocrinol Metab Clin North Am 2008;37:623-633, viii
11. Magkos F, Mohammed BS, Mittendorfer B. Effect of obesity on the plasma lipoprotein subclass profile in normoglycemic and normolipidemic men and women. Int J Obes (Lond) 2008;32:1655-1664
12. Abate N, Chandalia M. Role of subcutaneous adipose tissue in metabolic complications of obesity. Metab Syndr Relat Disord 2012;10:319-320
13. Ouchi N, Parker JL, Lugus JJ, et al. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97
14. Masuzaki H, Ogawa Y, Isse N, et al. Human obese gene expression. Adipocyte-specific expression and regional differences in the adipose tissue. Diabetes 1995;44:855-858
15. Jequier E. Leptin signaling, adiposity, and energy balance. Ann NY Acad Sci 2002;967:379-373
16. Stanley S, Wynne K, McGowan B, et al. Hormonal regulation of food intake. Physiol Rev 2005;85:1131-1158 (Pubitemid 41363743)
17. Ahima RS, Qi Y, Singhal NS. Adipokines that link obesity and diabetes to the hypothalamus. Prog Brain Res2006;153:155-174 (Pubitemid 44107415)
18. Seufert J, Kieffer TJ, Leech CA, et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab 1999;84:670-676 (Pubitemid 29075704)
19. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function. Diabetes 2004;53(Suppl 1):S152-S158 (Pubitemid 38168708)
20. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: A promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets2006;7:761-771 (Pubitemid 43827272)
21. Morrison CD, Huypens P, Stewart LK, et al. Implications of crosstalk between leptin and insulin signaling during the development of diet-induced obesity. Biochim Biophys Acta2009;1792:409-416
22. Niswender KD, Baskin DG, Schwartz MW. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol Metab 2004;15: 362-369 (Pubitemid 39223342)
23. Kim SK, Kim HJ, Ahn CW, et al. Hyperleptinemia as a robust risk factor of coronary artery disease and metabolic syndrome in type 2 diabetic patients. Endocr J 2008;55:1085-1092
24. Belgardt BF, Bruning JC. CNS leptin and insulin action in the control of energy homeostasis. Ann NY Acad Sci2010;1212:97-113
25. StepienM, Stepien A, Banach M, et al.New obesity indices and adipokines in normotensive patients and patients with hypertension: Comparative pilot analysis. Angiology 2013; May 1.[Epub ahead of print]; DOI: 10.1177/ 0003319713485807
26. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295 (Pubitemid 26033933)
27. Eriksson J, Valle T, Lindstrom J, et al. Leptin concentrations and their relation to body fat distribution and weight loss - A prospective study in individuals with impaired glucose tolerance. DPS-study group. Horm Metab Res 1999;31:616-619
28. Ozkan Y, Aydin S, Donder E, et al. Effect of orlistat on the total ghrelin and leptin levels in obese patients. J Physiol Biochem 2009;65:215-223
29. FarajM, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab 2003;88:1594-1602 (Pubitemid 36623375)
30. Chandran M, Phillips SA, Ciaraldi T, et al. Adiponectin: More than just another fat cell hormone? Diabetes Care2003;26:2442-2450 (Pubitemid 36993340)
31. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946 (Pubitemid 32756432)
32. Dridi S, Taouis M. Adiponectin and energy homeostasis: Consensus and controversy. J Nutr Biochem 2009;20: 831-839
33. Lele RD, Joshi SR, Gupte A. Association of adipocytokines (leptin, adiponectin TNF-alpha), insulin and proinsulin with diabetes - The Mumbai Obesity Project [MOP]. J Assoc Physicians India 2006;54:689-696 (Pubitemid 44371915)
34. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83 (Pubitemid 29299050)
35. Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2diabetic patients. Arterioscler Thromb Vasc Bio 2000;20:1595-1599 (Pubitemid 30353893)
36. Han SH, Sakuma I, Shin EK, et al. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: Basic and clinical studies. Prog Cardiovasc Dis 2009;52:126-140
37. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005;257:167-175 (Pubitemid 40193966)
38. Owecki M, Miczke A, Nikisch E, et al. Serum resistin concentrations are higher in human obesity but independent from insulin resistance. Exp Clin Endocrinol Diabetes 2011; 119:117-121
39. Jain SH, Massaro JM, Hoffmann U, et al. Cross-sectional associations between abdominal and thoracic adipose tissue compartments and adiponectin and resistin in the Framingham Heart Study. Diabetes Care 2009;32:903-908
40. Chen BH, Song Y, Ding EL, et al. Circulating levels of resistin and risk of type 2 diabetes in men and women: Results from two prospective cohorts. Diabetes Care 2009;32: 329-334
41. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-312 (Pubitemid 32151228)
42. Edwards CR, Hindle AK, Latham PS, et al. Resistin expression correlates with steatohepatitis in morbidly obese patients. Surg Endosc 2013;27:1310-1314
43. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: Possible link between visceral fat accumulation and vascular disease. Diabetes 1997;46:860-867 (Pubitemid 27188265)
44. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia1991;34:457-462
45. Appel SJ, Harrell JS, Davenport ML. Central obesity, the metabolic syndrome, and plasminogen activator inhibitor-1in young adults. J Am Acad Nurse Pract, 2005;17:535-541
46. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004;53:336-346 (Pubitemid 38174548)
47. Leal VD, Mafra D. Adipokines in obesity. Clin Chim Acta2013;419C:87-94
48. Yiannikouris F, Karounos M, Charnigo R, et al. Adipocytespecific deficiency of angiotensinogen decreases plasma angiotensinogen concentration and systolic blood pressure in mice. Am J Physiol Regul Integr Comp Physiol 2012; 302:R244-R251
49. Yasue S, Masuzaki H, Okada S, et al. Adipose tissue-specific regulation of angiotensinogen in obese humans and mice: Impact of nutritional status and adipocyte hypertrophy. Am J Hypertens 2010;23:425-431
50. Massiera F, Bloch-Faure M, Ceiler D, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J 2001;15:2727-2729
51. Poitou C, Viguerie N, Cancello R, et al. Serum amyloid A: Production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 2005;48:519-528 (Pubitemid 40487299)
52. Zhao Y, He X, Shi X, et al. Association between serum amyloid A and obesity: A meta-analysis and systematic review. Inflamm Res 2010;59:323-334
53. Ogasawara K, Mashiba S, Wada Y, et al. A serum amyloid A and LDL complex as a new prognostic marker in stable coronary artery disease. Atherosclerosis 2004;174:349-356 (Pubitemid 38597093)
54. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Curr Opin Lipidol 2011;22:302-307
55. Castan-Laurell I, Dray C, Attane C, et al. Apelin, diabetes, and obesity. Endocrine 2011;40:1-9
56. Boucher J, Masri B, Daviaud D, et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005;146:1764-1771 (Pubitemid 40396885)
57. Yu S, Zhang Y, Li MZ, et al. Chemerin and apelin are positively correlated with inflammation in obese type 2diabetic patients. Chin Med J (Engl) 2012;125:3440-3444
58. Heinonen MV, Laaksonen DE, Karhu T, et al. Effect of dietinduced weight loss on plasma apelin and cytokine levels in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2009;19:626-633
59. Kloting N, Graham TE, Berndt J, et al. Serum retinolbinding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab 2007;6:79-87 (Pubitemid 46995778)
60. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-2563 (Pubitemid 43882351)
61. Hammarstedt A, Graham TE, Kahn BB. Adipose tissue dysregulation and reduced insulin sensitivity in non-obese individuals with enlarged abdominal adipose cells. Diabetol Metab Syndr 2012;4:42
62. Youn BS, Kloting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes2008;57:372-377
63. Chang HM, Park HS, Park CY, et al. Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects. Metabolism 2010;59:1276-1281
64. Chang HM, Lee HJ, Park HS, et al. Effects of weight reduction on serum vaspin concentrations in obese subjects: Modification by insulin resistance. Obesity (Silver Spring)2010;18:2105-2110
65. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-430 (Pubitemid 40139988)
66. Zahorska-Markiewicz B, Olszanecka-Glinianowicz M, Janowska J, et al. Serum concentration of visfatin in obese women. Metabolism 2007;56:1131-1134 (Pubitemid 47021180)
67. Chang YH, Chang DM, Lin KC, et al. Visfatin in overweight/ obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: A metaanalysis and systemic review. Diabetes Metab Res Rev2011;27:515-527
68. Gong FY, Zhang SJ, Deng JY, et al. Zinc-alpha2-glycoprotein is involved in regulation of body weight through inhibition of lipogenic enzymes in adipose tissue. Int J Obes (Lond) 2009;33:1023-1030
69. Auguet T, Quintero Y, Riesco D, et al. New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue from morbidly obese women. BMC Med Genet 2011;12:60
70. Shibata R, Ouchi N, Takahashi R, et al. Omentin as a novel biomarker of metabolic risk factors. Diabetol Metab Syndr2012;4:37
71. Ng TW, Watts GF, Farvid MS, et al. Adipocytokines and VLDL metabolism: Independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005;54:795-802 (Pubitemid 40322084)
72. Matsuura F, Oku H, Koseki M, et al. Adiponectin accelerates reverse cholesterol transport by increasing high density lipoprotein assembly in the liver. Biochem Biophys Res Commun 2007;358:1091-1095 (Pubitemid 46829000)
73. Oku H, Matsuura F, Koseki M, et al. Adiponectin deficiency suppresses ABCA1 expression and ApoA-I synthesis in the liver. FEBS Lett 2007;581:5029-5033 (Pubitemid 47576080)
74. Tsubakio-Yamamoto K, Matsuura F, Koseki M, et al. Adiponectin prevents atherosclerosis by increasing cholesterol efflux from macrophages. Biochem Biophys Res Commun2008;375:390-394
75. Tsubakio-Yamamoto K, Sugimoto T, Nishida M, et al. Serum adiponectin level is correlated with the size of HDL and LDL particles determined by high performance liquid chromatography. Metabolism 2012;61:1763-1770
76. Lautamaki R, Ronnemaa T, Huupponen R, et al. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2diabetes mellitus and coronary artery disease. Metabolism2007;56:881- 886 (Pubitemid 46900837)
77. Giannessi D, Caselli C, Del Ry S, et al. Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure. Metabolism 2011;60:227-233
78. Bluher M, Williams CJ, Kloting N, et al. Gene expression of adiponectin receptors in human visceral and subcutaneous adipose tissue is related to insulin resistance and metabolic parameters and is altered in response to physical training. Diabetes Care 2007;30:3110-3115 (Pubitemid 350255258)
79. Labuzek K, Buldak L, Dulawa-Buldak A, et al. Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia. Pharmacol Rep 2011;63:1124-1136
80. Murao K, Wada Y, Nakamura T, et al. Effects of glucose and insulin on rat apolipoprotein A-I gene expression. J Biol Chem 1998;273:18959-18965 (Pubitemid 28366285)
81. Mooradian AD, Haas MJ, Wong NC. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes 2004;53:513-520 (Pubitemid 38270617)
82. Vanpatten S, Karkanias GB, Rossetti L, et al. Intracerebroventricular leptin regulates hepatic cholesterol metabolism. Biochem J 2004;379:229-233 (Pubitemid 38570094)
83. Huang W, Metlakunta A, Dedousis N, et al. Leptin augments the acute suppressive effects of insulin on hepatic very low-density lipoprotein production in rats. Endocrinology2009;150:2169-2174
84. Galata Z, Moschonis G, Makridakis M, et al. Plasma proteomic analysis in obese and overweight prepubertal children. Eur J Clin Invest 2011;41:1275-1283
85. Watts GF, Ooi EM, Chan DC. Therapeutic regulation of apoB100 metabolism in insulin resistance in vivo. Pharmacol Ther 2009;123:281-291
86. Perelas A, Safarika V, Vlachos IS, et al. Correlation between mesenteric fat thickness and serum apolipoproteins in patients with peripheral arterial occlusive disease. Lipids Health Dis 2012;11:125
87. Despres JP, Moorjani S, Lupien PJ, et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 1990;10:497-511 (Pubitemid 20220572)
88. Air EL, Strowski MZ, Benoit SC, et al. Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nat Med 2002;8:179-183 (Pubitemid 34155130)
89. Kolaczynski JW, Nyce MR, Considine RV, et al. Acute and chronic effects of insulin on leptin production in humans: Studies in vivo and in vitro. Diabetes 1996;45:699-701 (Pubitemid 26142812)
90. Widjaja A, Stratton IM, Horn R, et al. UKPDS 20: Plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects. J Clin Endocrinol Metab 1997;82:654-657 (Pubitemid 27068646)
91. Carey PE, Stewart MW, Ashworth L, et al. Effect of insulin therapy on plasma leptin and body weight in patients with type 2 diabetes. Horm Metab Res 2003;35:372-376 (Pubitemid 37102683)
92. Aas AM, Hanssen KF, Berg JP, et al. Insulin-stimulated increase in serum leptin levels precedes and correlates with weight gain during insulin therapy in type 2 diabetes. J Clin Endocrinol Metab 2009;94:2900-2906
93. Anderwald C, Brabant G, Bernroider E, et al. Insulindependent modulation of plasma ghrelin and leptin concentrations is less pronounced in type 2 diabetic patients. Diabetes 2003;52:1792-1798 (Pubitemid 36792472)
94. Halleux CM, Takahashi M, Delporte ML, et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun2001;288:1102-1107 (Pubitemid 33131713)
95. Fasshauer M, Klein J, Neumann S, et al. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2002;290:1084-1089 (Pubitemid 34687474)
96. Jacob AN, Salinas K, Adams-Huet B, et al. Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 2007;9:386-393 (Pubitemid 46502059)
97. Miyashita Y, Nishimura R, Nemoto M, et al. Prospective randomized study for optimal insulin therapy in type 2diabetic patients with secondary failure. Cardiovasc Diabetol2008;7:16
98. Zulian A, Cancello R, Girola A, et al. In vitro and in vivo effects of metformin on human adipose tissue adiponectin. Obes Facts 2011;4:27-33
99. Sharma PK, Bhansali A, Sialy R, et al. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2006;65:722-728 (Pubitemid 44772351)
100. Adamia N, Virsaladze D, Charkviani N, et al. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. Georgian Med News 2007:52-55
101. Evia-Viscarra ML, Rodea-Montero ER, Apolinar-Jimenez E, et al. The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: Controlled randomized clinical trial. J Pediatr Endocrinol Metab2012;25:41-49
102. Kendall D, Vail A, Amin R, et al. Metformin in obese children and adolescents: The MOCA trial. J Clin Endocrinol Metab 2013;98:322-329
103. Esteghamati A, Mousavizadeh M, Noshad S, et al. Genderdependent effects of metformin on vaspin and adiponectin in type 2 diabetes patients: A randomized clinical trial. Horm Metab Res 2013;45:319-325
104. Nakhjavani M, Morteza A, Asgarani F, et al. Metformin restores the correlation between serum-oxidized LDL and leptin levels in type 2 diabetic patients. Redox Rep2011;16:193-200
105. Kang ES, Park SY, Kim HJ, et al. The influence of adiponectin gene polymorphism on the rosiglitazone response in patients with type 2 diabetes. Diabetes Care 2005;28:1139-1144
106. Kim HJ, Kim SK, Shim WS, et al. Rosiglitazone improves insulin sensitivity with increased serum leptin levels in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;81:42-49
107. Chu CS, Lee KT, Lee MY, et al. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Cardiol 2006;97:646-650
108. von Bibra H, Diamant M, Scheffer PG, et al. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type2 diabetic patients without overt heart disease. Diab Vasc Dis Res 2008;5:310-318
109. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-362 (Pubitemid 41065039)
110. McTernan PG, Fisher FM, Valsamakis G, et al. Resistin and type 2 diabetes: Regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 2003;88:6098-6106 (Pubitemid 38033098)
111. McGee KC, Harte AL, da Silva NF, et al. Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFkappaB and JNK in human abdominal subcutaneous adipocytes. PLoS One 2011;6:e20287
112. Rizzo M, Vekic J, Koulouris S, et al. Effects of rosiglitazone on fasting and postprandial low- and high-density lipoproteins size and subclasses in type 2 diabetes. Angiology2010;61:584-590
113. Chen X, Yang L, Zhai SD. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: A meta-analysis of retrospective cohort studies. Chin Med J (Engl) 2012;125:4301-4306
114. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
115. Hohberg C, Pfutzner A, Forst T, et al. Successful switch from insulin therapy to treatment with pioglitazone in type2 diabetes patients with residual beta-cell function: Results from the PioSwitch study. Diabetes Obes Metab 2009;11: 464-471
116. Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res 2007;30:387-394 (Pubitemid 46958888)
117. Oz O, Tuncel E, Eryilmaz S, et al. Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones. Endocrine 2008;33: 101-105
118. Miyazaki Y, Mahankali A, Wajcberg E, et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312-4319 (Pubitemid 39244431)
119. Miyazaki Y, DeFronzo RA. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metab 2008;10:1204-1211
120. Shimizu H, Oh IS, Tsuchiya T, et al. Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in type 2 diabetic patients: A randomized study. Diabet Med 2006;23:253-257
121. Teranishi T, Ohara T, Maeda K, et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 2007;56:1418-1424 (Pubitemid 47404606)
122. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89:200-206 (Pubitemid 38183882)
123. Shah Z, Kampfrath T, Deiuliis JA, et al. Long-term dipeptidyl- peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011;124:2338-2349
124. Kim Chung le T, Hosaka T, Yoshida M, et al. Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression. Biochem Biophys Res Commun 2009;390:613-618
125. Samson SL, Gonzalez EV, Yechoor V, et al. Gene therapy for diabetes: Metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther 2008;16:1805-1812
126. Sathyanarayana P, Jogi M, Muthupillai R, et al. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. Obesity (Silver Spring)2011;19:2310-2315
127. Li L, Miao Z, Liu R, et al. Liraglutide prevents hypoadiponectinemia- induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol Med 2011;17:1168-1178
128. Rizzo M, Berneis K. The clinical relevance of low-densitylipoproteins size modulation by statins. Cardiovasc Drugs Ther 2006;20:205-217 (Pubitemid 44121036)
129. Rizzo M, Berneis K. The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates. Curr Med Res Opin 2007;23:1103-1111 (Pubitemid 46799594)
130. Chu CH, Lee JK, Lam HC, et al. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic type 2 diabetes. J Endocrinol Invest2008;31:42-47
131. Otto C, Otto B, Frost RJ, et al. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 2007; 44:65-68 (Pubitemid 46835447)
132. von Eynatten M, Schneider JG, Hadziselimovic S, et al. Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care, 2005, 28:754-755 (Pubitemid 40315347)
133. von Eynatten M, Liu D, Bluemm A, et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clin Endocrinol (Oxf) 2009;71:27-32
134. Kadoglou NP, Sailer N, Kapelouzou A, et al. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes. Acta Diabetol 2012;49:269-276
135. Ikewaki K, Terao Y, Ozasa H, et al. Effects of atorvastatin on nuclear magnetic resonance-defined lipoprotein sub- classes and inflammatory markers in patients with hypercholesterolemia. J Atheroscler Thromb 2009;16:51-56
136. van Hoek M, van Tol A, van Vark-van der Zee LC, et al. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes. Curr Med Res Opin 2009;25:93-101
137. Wierzbicki AS, Lumb PJ, Chik G, et al. Comparison of therapy with simvastatin 80mg and atorvastatin 80mg in patients with familial hypercholesterolaemia. Int J Clin Pract 1999;53:609-611 (Pubitemid 30018933)
138. Ascer E, Bertolami MC, Venturinelli ML, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004;177:161-166 (Pubitemid 39361151)
139. Bulcao C, Giuffrida FM, Ribeiro-Filho FF, et al. Are the beneficial cardiovascular effects of simvastatin and metformin also associated with a hormone-dependent mechanism improving insulin sensitivity? Braz J Med Biol Res2007;40:229-235 (Pubitemid 46237855)
140. Bellia A, Rizza S, Galli A, et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis 2010;210: 199-201
141. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45:1088-1093 (Pubitemid 40770310)
142. Hu Y, Tong G, Xu W, et al. Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis. Diab Vasc Dis Res 2009;6:262-268
143. Fraulob JC, Souza-Mello V, Aguila MB, et al. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin Sci (Lond) 2012;123:259-270
144. Takebayashi K, Suetsugu M, Matsumoto S, et al. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J 2009;102: 361-368
145. Caslake MJ, Stewart G, Day SP, et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis2003;171:245-253 (Pubitemid 37486076)
146. Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res 2009;26:958-964
147. Agouridis AP, Kostapanos MS, Tsimihodimos V, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract 2012;66:843-853
148. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
149. Damci T, Tatliagac S, Osar Z, et al. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med 2003;14:357-360 (Pubitemid 40090259)
150. Ogawa S, Takeuchi K, Sugimura K, et al. Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism2000;49:331-334 (Pubitemid 30146563)
151. Florentin M, Liberopoulos EN, Tellis CC, et al. Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: A pilot study. Angiology 2010;61:365-371
152. Yin WH, Jen HL, Chen JW, et al. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes Metab 2006;32:229-235 (Pubitemid 43966746)
153. Bajaj M, Suraamornkul S, Hardies LJ, et al. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007;50: 1723-1731 (Pubitemid 47036647)
154. Hiuge A, Tenenbaum A, Maeda N, et al. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007;27:635-641
155. Toruner F, Akbay E, Cakir N, et al. Effects of PPARgamma and PPARalpha agonists on serum leptin levels in dietinduced obese rats. Horm Metab Res 2004;36:226-230 (Pubitemid 38626410)
156. Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:850-852
157. Banks WA, Coon AB, Robinson SM, et al. Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes2004;53:1253-1260 (Pubitemid 38569011)
158. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-1563 (Pubitemid 43739414)
159. Superko HR, Garrett BC, King SB, 3rd, et al. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia. Am J Cardiol 2009;103: 387-392
160. Gouni-Berthold I, Berthold HK, Chamberland JP, et al. Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 2008;68:536-541 (Pubitemid 351388705)
161. Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on highdensity lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008;9:3151-3158
162. Chan DC, Watts GF, Gan SK, et al. Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B- 100 kinetics in insulin-resistant obese subjects on a weight loss diet. Diabetes Care 2010;33:1134-1139
163. Gupta M, Szmitko PE, Tsigoulis M, et al. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. J Cardiovasc Pharmacol 2010;56:241-245
164. Westphal S, Borucki K, Taneva E, et al. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007; 193:361-365 (Pubitemid 47058098)
165. Linke A, Sonnabend M, Fasshauer M, et al. Effects of extended- release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis2009;205:207-213
166. Worm D, Vinten J, Vaag A, et al. The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients. Eur J Endocrinol2000;143:389-395
167. Pan J, Lin M, Kesala RL, et al. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes Metab 2002;4:255-261 (Pubitemid 34814866)
168. Pan J, Van JT, Chan E, et al. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a)in diabetes. Metabolism 2002;51:1120-1127
169. Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 2007;115:477-482 (Pubitemid 350056758)
170. Derosa G, Maffioli P, Ferrari I, et al. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. Fundam Clin Pharmacol2011;25:642-651
171. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 2006;295:761-775 (Pubitemid 43244304)
172. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134 (Pubitemid 41653104)
173. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet2005;365:1389-1397 (Pubitemid 40523733)
174. Hollander PA, Amod A, Litwak LE, et al. Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: The ARPEGGIO trial. Diabetes Care 2010;33:605-607
175. Scheen AJ. The endocannabinoid system: A promising target for the management of type 2 diabetes. Curr Protein Pept Sci 2009;10:56-74
176. Kintscher U. The cardiometabolic drug rimonabant: After 2years of RIO-Europe and STRADIVARIUS. Eur Heart J2008;29:1709-1710 (Pubitemid 352019818)
177. Rosenstock J, Hollander P, Chevalier S, et al. SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: Effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2diabetes. Diabetes Care 2008;31:2169-2176
178. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study. Lancet2006;368:1660-1672 (Pubitemid 46048528)
179. Despres JP, Ross R, Boka G, et al. Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: The ADAGIOLipids trial. Arterioscler Thromb Vasc Biol 2009;29:416-423
180. De Luis DA, Conde R, Gonzalez Sagrado M, et al. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. Eur Rev Med Pharmacol Sci 2010;14:759-763
181. Fuke Y, Fujita T, Satomura A, et al. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment. Diabetes Technol Ther2010;12:393-398
182. Delles C, Raff U, Mimran A, et al. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens 2008;21:1330-1336
183. Mori H, Okada Y, Arao T, et al. Telmisartan at 80 mg/day increases high-molecular-weight adiponectin levels and improves insulin resistance in diabetic patients. Adv Ther2012;29:635-644
184. Kubik M, Chudek J, Adamczak M, et al. Telmisartan improves cardiometabolic profile in obese patients with arterial hypertension. Kidney Blood Press Res 2012;35:281-289
185. Komiya N, Hirose H, Kawabe H, et al. Effects of telmisartan therapy on metabolic profiles and serum high molecular weight (HMW)-adiponectin level in Japanese male hypertensive subjects with abdominal obesity. J Atheroscler Thromb 2009;16:137-142
186. Lee JM, Kim JH, Son HS, et al. Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension. J Int Med Res 2010;38:234-241
187. Inoue Y, Kakuma T, Nonaka Y, et al. Beneficial effect of combination therapy comprising angiotensin II receptor blocker plus calcium channel blocker on plasma adiponectin levels. Clin Exp Hypertens 2010;32:21-28